Add this result to my export selection Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 March 2011 Recommendation ID TA217/1 Question Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 January 2013 Recommendation ID TA272/1 Question Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2011 Recommendation ID TA216/1 Question Research should be carried out to compare the clinical effectiveness of bendamustine with chlorambucil Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Golimumab for the treatment of psoriatic arthritis (TA220/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 April 2011 Recommendation ID TA220/1 Question NICE highlighted the importance of collecting further data within registries of patients receiving biological Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Mannitol dry powder for inhalation for treating cystic fibrosis (TA266/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 November 2012 Recommendation ID TA266/1 Question NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 September 2014 Recommendation ID TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 April 2014 Recommendation ID TA310/1 Question NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2015 Recommendation ID TA333/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Sofosbuvir for treating chronic hepatitis C (TA330/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2015 Recommendation ID TA330/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Holoclar for treating limbal stem cell deficiency after eye burns (TA467/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 August 2017 Recommendation ID TA467/2 Question NICE recommended that further research should be designed to generate robust evidence of the clinical- Type: Evidence Uncertainties (Remove filter)